251 related articles for article (PubMed ID: 27347670)
1. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.
Zaorsky NG; Shaikh T; Murphy CT; Hallman MA; Hayes SB; Sobczak ML; Horwitz EM
Cancer Treat Rev; 2016 Jul; 48():50-60. PubMed ID: 27347670
[TBL] [Abstract][Full Text] [Related]
2. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
Burri RJ; Stone NN; Unger P; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
[TBL] [Abstract][Full Text] [Related]
4. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
[TBL] [Abstract][Full Text] [Related]
8. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
9. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
10. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
12. Impact of race on biochemical disease recurrence after prostate brachytherapy.
Yamoah K; Stone N; Stock R
Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
[TBL] [Abstract][Full Text] [Related]
13. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.
Martell K; Mendez LC; Chung HT; Tseng CL; Alayed Y; Cheung P; Liu S; Vesprini D; Chu W; Wronski M; Szumacher E; Ravi A; Loblaw A; Morton G
Radiother Oncol; 2019 Dec; 141():149-155. PubMed ID: 31522882
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of hypofractionation for primary management of prostate cancer.
Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
17. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
18. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
19. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
20. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]